Sodium Carbonate → 5-(11-fluoro-6-(hydroxymethyl)-6H-pyrido[2',3':5,6][1,3]oxazino[3,4-a]indol-2-yl)-2-(6-methoxypyridin-3-yl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide

HRID 595559ノート

反応式

HRID 595559 の反応式
Cl[C:2]1[CH:3]=[CH:4][C:5]2[O:18][CH:17]([CH2:19][OH:20])[N:8]3[C:9]4[CH:10]=[CH:11][CH:12]=[C:13]([F:16])[C:14]=4[CH:15]=[C:7]3[C:6]=2[N:21]=1.[CH3:22][O:23][C:24]1[N:29]=[CH:28][C:27]([C:30]2[O:31][C:32]3[CH:42]=[C:41]([N:43]([CH3:48])[S:44]([CH3:47])(=[O:46])=[O:45])[C:40](B4OC(C)(C)C(C)(C)O4)=[CH:39][C:33]=3[C:34]=2[C:35]([NH:37][CH3:38])=[O:36])=[CH:26][CH:25]=1.C(=O)([O-])[O-].[Na+].[Na+].CC(C1C=C(C(C)C)C(C2C=CC=CC=2P(C2CCCCC2)C2CCCCC2)=C(C(C)C)C=1)C>O1CCOCC1.O.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.[Pd].[Pd]>[F:16][C:13]1[C:14]2[CH:15]=[C:7]3[C:6]4[N:21]=[C:2]([C:40]5[C:41]([N:43]([CH3:48])[S:44]([CH3:47])(=[O:46])=[O:45])=[CH:42][C:32]6[O:31][C:30]([C:27]7[CH:28]=[N:29][C:24]([O:23][CH3:22])=[CH:25][CH:26]=7)=[C:34]([C:35]([NH:37][CH3:38])=[O:36])[C:33]=6[CH:39]=5)[CH:3]=[CH:4][C:5]=4[O:18][CH:17]([CH2:19][OH:20])[N:8]3[C:9]=2[CH:10]=[CH:11][CH:12]=1

参加物

8

反応条件

温度
70 °C

実験手順

To a solution of (S or R)-(2-chloro-11-fluoro-6H-pyrido[2′,3′:5,6][1,3]oxazino[3,4-a]indol-6-yl)methanol (35 mg, 0.115 mmol), 2-(6-methoxypyridin-3-yl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzofuran-3-carboxamide (50 mg, 0.097 mmol) and sodium carbonate (20 mg, 0.188 mmol) in 2 mL of 1,4-dioxane and 0.2 mL of water was added Pd2(dba)3 (10 mg) and X-Phos (10 mg) under nitrogen. The reaction mixture was heated at 70° C. for 16 hours and concentrated in vacuo to remove 1,4-dioxane. And then the residue was suspended in water and extracted with EtOAc. The combined organic phase was washed with brine, dried over Na2SO4 and concentrated. The residue was purified by prep-HPLC to give the product of (S or R)-5-(11-fluoro-6-(hydroxymethyl)-6H-pyrido[2′,3′:5,6][1,3]oxazino[3,4-a]indol-2-yl)-2-(6-methoxypyridin-3-yl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (30 mg, yield: 47%). 1H-NMR (CDCl3, 400 MHz) δ 8.72 (d, J=2.4 Hz, 1H), 8.14˜8.17 (m, 1H), 7.99 (s, 1H), 7.64 (s, 1H), 7.43˜7.48 (m, 2H), 7.14˜7.23 (m, 3H), 6.81˜6.86 (m, 2H), 6.42˜6.45 (m, 1H), 6.06 (brs, 1H), 4.01 (s, 3H), 3.98˜4.00 (m, 1H), 3.85˜3.88 (m, 1H), 3.37 (s, 3H), 2.96 (d, J=4.8 Hz, 3H), 2.72 (s, 3H), 2.27 (s, 1H). MS (M+H)+: 658.

後処理

  1. concentrationconcentrated in vacuo
  2. customto remove 1,4-dioxane
  3. extractionextracted with EtOAc
  4. washThe combined organic phase was washed with brine
  5. dry with materialdried over Na2SO4
  6. concentrationconcentrated
  7. customThe residue was purified by prep-HPLC

出典と根拠

ORDレコード
ord-2905b0fd7d5a4e90b1f8097366b082ef
出典データセット
uspto-grants-2016_01
特許番号
US09242998B2

反応ノート

読み込み中…